Search results
Results from the WOW.Com Content Network
Otsuka Pharmaceutical Co., Ltd. (大塚製薬株式会社, Ōtsuka Seiyaku Kabushiki-gaisha) (TYO: 4578), abbreviated OPC, is a pharmaceutical company headquartered in Tokyo, Osaka and Naruto, Japan. The company was established August 10, 1964.
In 2011, Astex Therapeutics Limited and SuperGen, Inc. (US) merged. [10] Following the acquisition, SuperGen, Inc. changed its name to Astex Pharmaceuticals, Inc., and began trading under the ticker symbol ASTX on NASDAQ. [11] The combined Astex entities were subsequently acquired by Otsuka Pharmaceutical in October 2013 for around USD $900 ...
Akebia Therapeutics Inc (NASDAQ: AKBA) and Otsuka Holdings (OTC: OTSKY) separately announced to call for licensing and co-development agreement for vadadustat. Otsuka sent a written notice to ...
Otsuka will pay $800 million to Jnana shareholders along with up to $325 million in development and regulatory milestones, the Japanese Japan's Otsuka Pharma to pay up to $1.1 billion to acquire ...
In 2007, eight of the 20 best-selling biotechnology drugs in the U.S. are therapeutic monoclonal antibodies. [44] This rapid growth in demand for monoclonal antibody production has been well accommodated by the industrialization of mAb manufacturing. [45]
According to this fan, Olay products have been a family skin-care secret for years: "My mother-in-law, who passed away a few years back at 95, swore by Olay. No one would have guessed she was her ...
These plans prevents price inflation through formulary management, independent clinical review of new products, reference-based pricing, the LCA, and limited use program. [131] In reviewing formularies, the drug program reviews the therapeutic advantage of one product over the existing formulary, and only adds new drugs if program costs are ...
During the European Hematology Association (EHA) conference, Forma Therapeutics Holdings Inc (NASDAQ: FMTX) presented updated results from the 12-week open-label extension (OLE) of etavopivat's ...